Media & PR
Dr Ralph Warsinsky
Binger Strasse 173
55216 Ingelheim am Rhein
Ex US & UK Medical Media Only
Ingelheim, Germany and Indianapolis, US, 11 June, 2013 – Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the companies’ diabetes alliance will have a strong scientific and clinical presence at the 73rd American Diabetes Association® (ADA) Scientific Sessions in Chicago, 21–25 June, with 34 posters, abstracts and an oral presentation.
A total of 17 clinical and pre-clinical abstracts for the investigational agent empagliflozin will be presented, including three late-breaker abstracts. Empagliflozin is a member of the sodium glucose cotransporter 2 (SGLT2) inhibitor class of drugs and is being investigated for the reduction of blood glucose levels in adults with Type 2 Diabetes (T2D). The emerging SGLT2 inhibitor class removes excess glucose through the urine by reducing glucose reabsorption in the kidney.
Details of clinical empagliflozin presentations and published abstracts are as follows:1
A total of 17 clinical and pre-clinical abstracts regarding linagliptin will also be presented, including two late-breaker abstracts. Linagliptin is an inhibitor of the enzyme DPP-4 which breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that are involved with regulating blood sugar.2
Details of all clinical presentations and published abstracts are as follows:1
Linagliptin, which is marketed as Trajenta® 5mg tablets in Europe, is a once-daily tablet used along with diet and exercise to improve glycaemic control in adults with Type 2 Diabetes. Linagliptin should not be used in patients with Type 1 Diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). Linagliptin is a DPP-4 inhibitor that does not require dose adjustments that may be brought about by declining renal function or hepatic impairment.
An estimated 371 million people worldwide have Type 1 or Type 2 Diabetes.3 Type 2 Diabetes is the most common type, accounting for an estimated 90–95% of all diabetes cases.2 Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin.4
Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centres on three compounds representing several of the largest diabetes treatment classes. This alliance leverages the companies’ strengths as two of the world’s leading pharmaceutical companies, combining Boehringer Ingelheim’s solid track record of research-driven innovation and Lilly’s innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Find out more about the alliance at www.boehringer-ingelheim.com or www.lilly.com.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organisations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions – from medicines to support programmes and more – to make lives better.
For more information, visit www.lillydiabetes.com.
*Empagliflozin is an investigational compound. Its safety and efficacy have not been established.
This press release contains forward looking statements about empagliflozin, an investigational compound for the treatment of Type 2 Diabetes and linagliptin, a DPP-4 inhibitor approved for the treatment of Type 2 Diabetes along with diet and exercise. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialisation. There is no guarantee that future study results and patient experience will be consistent with study findings to date that linagliptin will be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
1Abstract book for the American Diabetes Association (ADA) 73rd Scientific Sessions
2Tradjenta® (linagliptin) tablets. Highlights of Prescribing Information. Initial US Approval: 2011.
3International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet. 2012.
4International Diabetes Federation. IDF Diabetes Atlas, 5th Edition: What is Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes. Accessed on: April 4, 2013